M&G PLC Bei Gene, Ltd. Transaction History

M&G PLC

$16.2 Trillion
Q4 2024

A detailed history of M&G PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, M&G PLC holds 193,163 shares of BGNE stock, worth $43.8 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

193,163

Previous 173,075 11.61%

Holding current value

$43.8 Million

Previous $38.9 Billion 8.23%

% of portfolio

0.22%

Previous 0.14%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$174.72 - $246.04 $3.51 Million - $4.94 Million	20,088 Added 11.61%	193,163 $35.7 Billion
Q3 2024 Oct 31, 2024	SELL	$143.93 - $224.51 $964,906 - $1.51 Million	-6,704 Reduced 3.73%	173,075 $38.9 Billion
Q2 2024 Jul 16, 2024	SELL	$129.52 - $174.32 $1.33 Million - $1.79 Million	-10,277 Reduced 5.41%	179,779 $25.7 Billion
Q1 2024 May 10, 2024	BUY	$141.8 - $181.47 $26.9 Million - $34.5 Million	190,056 New	190,056 $29.6 Billion

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

42.4M

Call Options Held

135K

Put Options Held

111K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&G PLC, based on Form 13F filings with the SEC.

News

Stay updated on M&G PLC with notifications on news.

Account